Clinical trials: Insulin Pump
Type1 Diabetes Mellitus
A Pilot Test of t:Slim X2 With Control-IQ Technology
A 36-48 hour admission testing the t:slim X2 with Control-IQ Technology
- Trial name
- NCT03368937
- Testing
- Tandem t:slim X2 with Control-IQ Technology
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Virginia
Type 1 Diabetes
Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes
The study team will be comparing two investigational Artificial Pancreas (AP) systems that the UVA Center for Diabetes Technology has developed.
- Trial name
- RocketAP (NCT04545567)
- Testing
- RocketAP, USS Virginia
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Virginia
Type 1 Diabetes Mellitus
Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin
The purpose of this proposed study is to assess the use of a new feature of the Control-IQ system, MyTDI.
- Trial name
- NCT03804983
- Testing
- Hybrid Closed Loop (HCL), Control-IQ with MyTDI
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Virginia
Type 1 Diabetes Mellitus
FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump
This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with…
- Trial name
- NCT03977727
- Testing
- Fiasp®, Novolog®, 670G hybrid closed loop continuous subcutaneous insulin infusion system
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Texas Diabetes & Endocrinology, P.A.
Diabetes Mellitus, Type 1
A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps
This study evaluated a blood sugar lowering insulin, LY900014, delivered by an insulin pump continuously under the skin. The study was conducted in participants with type 1 diabetes mellitus to investigate how the human body…
- Trial name
- NCT02703324
- Testing
- LY900014, Insulin Lispro
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
A Study of t:Slim X2 With Control-IQ Technology
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for children with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
- Trial name
- DCLP5 (NCT03844789)
- Testing
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Control Group
- Where
- 4 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Virginia
Type 1 Diabetes
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes…
- Trial name
- NCT04796779
- Testing
- Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- Marc Breton
Type 1 Diabetes
Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes
A phase 4 study evaluating the efficacy of mealtime control with Afrezza in combination with an automated insulin pump or insulin degludec in adult subjects with type 1 diabetes
- Trial name
- ABC (NCT05243628)
- Testing
- Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID)
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Mannkind Corporation
Diabetes Mellitus, Type 2
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily…
- Trial name
- OpT2mise (NCT01182493)
- Testing
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Where
- 36 sites in United States, Austria and 11 more
- Volunteers
- 331 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections.
- Trial name
- STAR2 (NCT00530023)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Diabetes Assistant (DiAs) Control-to-Range (CTR) Nocturnal Closed-Loop Camp Study
The primary goal is to test the function of the Diabetes Assistant (DiAs) enhanced control-to-range (CTR) controller in a closely monitored diabetes camp setting. The camp setting will allow us to obtain pilot efficacy data.
- Trial name
- NCT01973413
- Testing
- Diabetes Assistant (DiAs), Tandem t:slim Insulin Pump, Dexcom G4 Platinum sensor
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily…
- Trial name
- VIVID (NCT02561078)
- Testing
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 420 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
Prospective Study of the Impact of Insulin Pump Therapy in Young Children With Type 1 Diabetes
The purpose of the study is to examine glycemic and neuropsychological outcomes in very young children with Type I diabetes who are being started on insulin pumps and to compare their outcomes to children who are not utilizing…
- Trial name
- NCT00727220
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Indiana University
Diabetes Mellitus, Type 1
Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use
Patients will continue to use their current insulin pump for this study. Patients will receive insulin lispro and insulin aspart during this study.
- Trial name
- NCT01134107
- Testing
- Insulin Lispro 6 Day (6D), Insulin Aspart 6 Day (6D)
- Where
- 15 sites in France, Germany and 1 more
- Volunteers
- 133 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes
New Strategies for Postprandial Glycemic Control Using Insulin Pump Therapy
Achieving near-normoglycemia has been established as the main objective for most patients with type 1 diabetes (T1DM). However, insulin dosing is an empirical process and its success is highly dependent on the patients' and…
- Trial name
- NCT01550809
- Testing
- iBolus, tBolus (traditional bolus)
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Type 1 Diabetes, Type 2 Diabetes
User Evaluation of the MiniMed 640G Insulin Pump
This four center international study will include two United Kingdom National Health Service centers, and two centers in Melbourne, Australia.
- Trial name
- NCT01991548
- Testing
- MiniMed® 640G Insulin Pump and Guardian® Link Transmitter
- Where
- 4 sites in Australia, United Kingdom
- Volunteers
- 52 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Outpatient Study to Evaluate Safety and Effectiveness of the Low Glucose Suspend Feature
Introduction: The purpose of the pivotal In Home study is to collect clinical data on the safety and efficacy of the Paradigm LGS System in the actual use environment and by the intended use population.
- Trial name
- ASPIRE (NCT01497938)
- Testing
- Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature, Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump
- Where
- 17 sites in United States
- Volunteers
- 247 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 1
Education Effectiveness for Type 1 Diabetes Mellitus on Insulin Pump Therapy
The purpose of this study is to assess the effectiveness of structured group education on glycemic control and Quality of Life (QoL) among users of continuous subcutaneous insulin infusions (CSII).
- Trial name
- EASEDIAP (NCT02423993)
- Testing
- Education by structured programme, CSII, CGM-RT
- Volunteers
- 77 people
- Sponsor
- Endocrinology Research Centre, Moscow
Diabetes Mellitus
MEDTRUM A7+ TouchCare Insulin Patch Pump (MedInPS)
Demonstration study of the interest of the MEDTRUM A7+ TouchCare insulin patch pump versus INSULET Omnipod® patch pump
- Trial name
- MedInPS (NCT04223973)
- Testing
- Medtrum A7+ insulin Pump, Lab A1C
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Medtrum France
Diabetes Mellitus
Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy
Type I diabetes (T1DM) is the second most common chronic illness effecting children in the USA. Worldwide, Type I diabetes is increasing in incidence, and its underlying etiology remains elusive.
- Trial name
- ktpump (NCT00574405)
- Testing
- MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®]), CSII (Animas Corporation insulin pump, model IR 1200)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Arkansas Children's Hospital Research Institute